var data={"title":"Carbamazepine poisoning","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Carbamazepine poisoning</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/contributors\" class=\"contributor contributor_credentials\">Spencer Greene, MD, MS, FACEP, FACMT</a></dd><dd><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/contributors\" class=\"contributor contributor_credentials\">Ayrn O'Connor, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/contributors\" class=\"contributor contributor_credentials\">Stephen J Traub, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/contributors\" class=\"contributor contributor_credentials\">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/contributors\" class=\"contributor contributor_credentials\">Jonathan Grayzel, MD, FAAEM</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 04, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> has been used for many years for the treatment of both partial and generalized seizures, as well as trigeminal neuralgia. It has also been used as a mood stabilizer and for treatment of neuropathic pain syndromes.</p><p>In 2014, the American Association of Poison Control Centers reported 3734 toxic exposures to <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/1\" class=\"abstract_t\">1</a>]. Of these, 1880 were isolated ingestions. There were no deaths, and 62 patients experienced major toxicity, defined as life-threatening or resulting in significant disability [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>The toxicology, diagnosis, and management of acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning are discussed here. The clinical use of carbamazepine and chronic complications related to its use are reviewed separately. (See <a href=\"topic.htm?path=overview-of-the-management-of-epilepsy-in-adults\" class=\"medical medical_review\">&quot;Overview of the management of epilepsy in adults&quot;</a> and <a href=\"topic.htm?path=seizures-and-epilepsy-in-children-initial-treatment-and-monitoring\" class=\"medical medical_review\">&quot;Seizures and epilepsy in children: Initial treatment and monitoring&quot;</a> and <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> interacts with multiple receptors and ion channels. Its therapeutic effect results from binding to sodium channels in their inactivated state, which inhibits neuron depolarization and decreases glutamate release [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/2\" class=\"abstract_t\">2</a>]. It is also anticholinergic, a property that is more relative in overdose than the therapeutic setting [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=anticholinergic-poisoning\" class=\"medical medical_review\">&quot;Anticholinergic poisoning&quot;</a>.)</p><p>In <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity, sodium channel blockade may manifest as cardiovascular toxicity, particularly prolongation of the QRS interval. This conduction abnormality predisposes patients to ventricular arrhythmias and hypotension [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/4\" class=\"abstract_t\">4</a>].</p><p><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> appears to have a paradoxical effect on adenosine receptors. In therapeutic doses, the drug inhibits presynaptic reuptake of adenosine, resulting in modulation and inhibition of glutamate neurotransmission [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/5,6\" class=\"abstract_t\">5,6</a>]. In overdose, carbamazepine antagonizes adenosine receptors, resulting in a proconvulsant effect, which explains the seizure activity commonly seen in carbamazepine toxicity [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">KINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> is available in both immediate-release and controlled-release tablets and an immediate-release oral suspension. Absorption of therapeutic doses of an immediate-release formulation occurs in 3 to 12 hours [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/2,7\" class=\"abstract_t\">2,7</a>]. In overdose, absorption is erratic and may be prolonged, with peak levels occurring over 96 hours after ingestion of a controlled-release formulation [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8\" class=\"abstract_t\">8</a>]. The volume of distribution ranges from 0.8 to 1.8 <span class=\"nowrap\">L/kg,</span> and protein binding is estimated to be between 75 and 90 percent [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/9\" class=\"abstract_t\">9</a>].</p><p><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> undergoes hepatic metabolism, primarily through cytochrome P450 (CYP) 3A4 [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/10\" class=\"abstract_t\">10</a>]. More than 30 metabolites have been identified [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/7,11\" class=\"abstract_t\">7,11</a>]. The most important of these are carbamazepine-10,11-epoxide, which has intrinsic anticonvulsant activity, and trans-10-11-dihydroxy-10,11-dihydrocarbamazepine, an arene oxide metabolite believed to be responsible for the hypersensitivity reactions and teratogenic effects of carbamazepine [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> is a CYP 3A4 substrate as well as an inducer of multiple cytochrome P450 isoenzymes and may be subject to a number of drug-drug interactions (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 1</a>). Toxic levels of carbamazepine may result from CYP 3A4 inhibition due to <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>, and <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">cimetidine</a>, among other drugs [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/2,14,15\" class=\"abstract_t\">2,14,15</a>]. Conversely, CYP 3A4 inducers, such as <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> and <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>, may decrease carbamazepine levels [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/10\" class=\"abstract_t\">10</a>]. Plasma levels of many medications, including <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> and <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a> [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/16,17\" class=\"abstract_t\">16,17</a>], are reduced in the setting of carbamazepine use. Carbamazepine induces its own metabolism, and dosage requirements increase with chronic use [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/11\" class=\"abstract_t\">11</a>].</p><p><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a>'s elimination half-life demonstrates significant variability with therapeutic dosing, ranging from 12 to 17 hours following chronic therapeutic use [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/2\" class=\"abstract_t\">2</a>]. The half-life can be significantly prolonged following overdose and averages 35 hours following a single overdose and 20 hours after multiple dosages [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/18\" class=\"abstract_t\">18</a>]. In overdose, carbamazepine's elimination is thought to display zero-order kinetics [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinicians should consider the diagnosis of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity in any patient with cerebellar symptoms, central nervous system (CNS) depression, and signs of the anticholinergic toxidrome, particularly if the patient is known to have a seizure disorder or access to anticonvulsants.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">History</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Important historical information in the patient with suspected <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Identity of any ingested pills, including dose and formulation (eg, immediate-release or controlled-release)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approximate number of pills ingested</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Time of ingestion</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Whether the patient takes <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> or any other medication chronically</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible coingestants</p><p/><p>Other helpful information includes symptoms prior to seeking medical care (such as vomiting, prolonged unconsciousness, or seizure activity) and whether any treatment was provided prior to arrival.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Examination and clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> toxicity frequently presents with neurologic, cardiovascular, and anticholinergic symptoms. Patients with mild carbamazepine toxicity or those presenting shortly after the ingestion when absorption remains incomplete may demonstrate drowsiness, nystagmus, and tachycardia [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8,20-24\" class=\"abstract_t\">8,20-24</a>]. More severe intoxication may manifest as lethargy, seizure, coma, hypotension, or arrhythmia [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/21-25\" class=\"abstract_t\">21-25</a>]. Signs and symptoms of anticholinergic toxicity are expected. Toxicity may be prolonged due to carbamazepine's delayed and erratic absorption. (See <a href=\"topic.htm?path=anticholinergic-poisoning\" class=\"medical medical_review\">&quot;Anticholinergic poisoning&quot;</a>.)</p><p>Tachycardia is common following <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> overdose. Hypotension is observed in moderate to severe poisoning and may be due to direct negative inotropic effects. Hyperthermia may be a result of anticholinergic effects (impaired heat dissipation) or from seizure activity [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/21,24\" class=\"abstract_t\">21,24</a>].</p><p>Neurologic examination typically reveals altered mental status. The patient may be agitated, but CNS depression, ranging from drowsiness to coma, is more common [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/20-26\" class=\"abstract_t\">20-26</a>]. Coma is often cyclical and consciousness may fluctuate abruptly from alert to comatose [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/20,25\" class=\"abstract_t\">20,25</a>]. Ataxia and dysmetria (loss of coordinated movement) are common [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/22,25\" class=\"abstract_t\">22,25</a>].</p><p>Seizures may occur, particularly in patients with underlying epilepsy [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/21-25\" class=\"abstract_t\">21-25</a>]. Seizures are often self-limited but may rarely progress to status epilepticus [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/21,25\" class=\"abstract_t\">21,25</a>]. Myoclonus, hypertonia, hypotonia, and choreoathetosis have all been described in the setting of acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/23,24,27\" class=\"abstract_t\">23,24,27</a>]. A single case report has described sensorineural hearing loss [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Ocular examination frequently reveals nystagmus and mydriasis, and occasionally ophthalmoplegia [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8,19,23,27\" class=\"abstract_t\">8,19,23,27</a>]. Oropharyngeal examination often reveals dry mucus membranes, and may show signs of trauma, which can occur from a fall due to a depressed level of consciousness or seizure activity.</p><p>Abdominal examination may reveal hypoactive or absent bowel sounds and the urinary bladder may be palpable from urinary retention, both due to the anticholinergic effects of the drug. Abdominal tenderness is rare. Pancreatitis is rare, but has been described [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/29\" class=\"abstract_t\">29</a>].</p><p>The skin may be hot, dry, and flushed and the axillae dry due to anticholinergic effects. One case report describes bullous eruptions following <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/30\" class=\"abstract_t\">30</a>].</p><p>Chronic use of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> has been associated with leukopenia, agranulocytosis, and rarely, aplastic anemia. Other chronic side effects can include drug hypersensitivity and Stevens-Johnson syndrome. Chronic side effects from carbamazepine therapy are discussed separately. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H3\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Carbamazepine'</a> and <a href=\"topic.htm?path=aplastic-anemia-pathogenesis-clinical-manifestations-and-diagnosis#H7\" class=\"medical medical_review\">&quot;Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis&quot;, section on 'Drugs'</a> and <a href=\"topic.htm?path=drug-allergy-classification-and-clinical-features#H31\" class=\"medical medical_review\">&quot;Drug allergy: Classification and clinical features&quot;, section on 'Drug-induced hypersensitivity syndrome'</a> and <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> toxicity may present in a similar fashion to other poisonings as well as metabolic, infectious, or structural central nervous system (CNS) disorders.</p><p>The toxicologic differential diagnosis is based largely on the presenting symptoms. If anticholinergic toxicity is present, anticholinergic agents (eg, tricyclic antidepressants, antihistamines, phenothiazines, and <a href=\"topic.htm?path=cyclobenzaprine-drug-information\" class=\"drug drug_general\">cyclobenzaprine</a>) should be considered. Cerebellar abnormalities and CNS depression should prompt consideration of sedative-hypnotic toxicity or toxic effects from other anticonvulsants, such as <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, valproic acid, or <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a>. Serum drug testing may help refine the differential diagnosis. (See <a href=\"topic.htm?path=anticholinergic-poisoning\" class=\"medical medical_review\">&quot;Anticholinergic poisoning&quot;</a> and <a href=\"topic.htm?path=tricyclic-antidepressant-poisoning\" class=\"medical medical_review\">&quot;Tricyclic antidepressant poisoning&quot;</a> and <a href=\"topic.htm?path=phenytoin-poisoning\" class=\"medical medical_review\">&quot;Phenytoin poisoning&quot;</a> and <a href=\"topic.htm?path=valproic-acid-poisoning\" class=\"medical medical_review\">&quot;Valproic acid poisoning&quot;</a> and <a href=\"topic.htm?path=benzodiazepine-poisoning-and-withdrawal\" class=\"medical medical_review\">&quot;Benzodiazepine poisoning and withdrawal&quot;</a>.)</p><p>Carbon monoxide (CO) poisoning can present with a variety of signs and symptoms that may resemble <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning. If CO poisoning is considered, a carboxyhemoglobin level should be obtained. (See <a href=\"topic.htm?path=carbon-monoxide-poisoning\" class=\"medical medical_review\">&quot;Carbon monoxide poisoning&quot;</a>.)</p><p>CNS pathology, especially cerebellar disease, can present with findings similar to acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning. Hypoglycemia, encephalitis-meningitis, status epilepticus, hepatic encephalopathy, subarachnoid hemorrhage, and stroke all may resemble carbamazepine toxicity. Hypoglycemia can be quickly excluded by finger-stick glucose testing. Neurologic imaging and analysis of the cerebrospinal fluid can distinguish many of these conditions from carbamazepine toxicity. (See <a href=\"topic.htm?path=hypoglycemia-in-adults-clinical-manifestations-definition-and-causes\" class=\"medical medical_review\">&quot;Hypoglycemia in adults: Clinical manifestations, definition, and causes&quot;</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-acute-bacterial-meningitis-in-adults\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of acute bacterial meningitis in adults&quot;</a> and <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=hepatic-encephalopathy-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatic encephalopathy in adults: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">LABORATORY EVALUATION</span></p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">General diagnostic testing in overdose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine laboratory evaluation of the poisoned patient should include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">Acetaminophen</a> and salicylate levels, to rule out these common coingestions</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnancy test in women of childbearing age</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Serum carbamazepine concentration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> concentrations should be followed serially in an acute overdose. Serum concentrations may not peak for over 96 hours; levels should be obtained every four to six hours until there is a definite downward trend and the patient is improving clinically [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8\" class=\"abstract_t\">8</a>]. Therapeutic concentrations of carbamazepine range from 4 to 12 <span class=\"nowrap\">mcg/mL</span> (17 to 51 <span class=\"nowrap\">micromol/L)</span>.</p><p>The relationship between <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> levels and particular toxicities varies. Carbamazepine concentrations above 40 <span class=\"nowrap\">mcg/mL</span> (170 <span class=\"nowrap\">micromol/L)</span> correlate with an increased risk for seizures, apnea, dystonia, hypotension, and coma [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/22,25,27,31\" class=\"abstract_t\">22,25,27,31</a>]. The relationship between the serum carbamazepine concentration and seizure risk is less consistent, but one small retrospective case series reported that seizures occurred exclusively in epileptic patients and with a serum carbamazepine concentration greater than 25 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Ancillary testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rarely, severe <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity can cause QRS prolongation and arrhythmia. Patients should be placed on continuous cardiac monitoring and a 12-lead electrocardiogram (ECG) should be obtained. Should QRS prolongation develop, <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> should be administered and a repeat ECG obtained. (See <a href=\"#H14450270\" class=\"local\">'QRS interval prolongation'</a> below.)</p><p>Sinus tachycardia is the most frequently observed cardiac effect of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, but bradycardia, atrioventricular block, premature ventricular contractions, ventricular tachycardia, and junctional escape rhythms have all been attributed to carbamazepine toxicity [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Rhabdomyolysis may be present following an acute overdose of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, if the patient has seized or experienced a prolonged period of unconsciousness. Creatine phosphokinase should be obtained initially and followed serially if elevated or if the history suggests the patient is at risk for rhabdomyolysis. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rhabdomyolysis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of rhabdomyolysis&quot;</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-heme-pigment-induced-acute-kidney-injury\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of heme pigment-induced acute kidney injury&quot;</a>.)</p><p>Imaging is not routinely needed following <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> ingestion. However, if historical or examination findings suggest aspiration or pulmonary edema, a chest radiograph should be obtained. If the diagnosis is in question, concomitant pathology is suspected, or the patient has evidence of external head trauma, computed tomography of the head is indicated.</p><p>If urine toxicology testing is performed, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> may trigger a false positive result for tricyclic antidepressants because of the structural similarity among these drugs [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/32-34\" class=\"abstract_t\">32-34</a>].</p><p>Laboratory tests may reveal evidence of chronic toxicity. Examples include leukopenia, or rarely agranulocytosis, on a complete blood count [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/35\" class=\"abstract_t\">35</a>], or hyponatremia on a basic metabolic profile [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/36\" class=\"abstract_t\">36</a>]. Liver function tests (LFTs) are elevated in up to 30 percent of patients using <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> chronically [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/20,37\" class=\"abstract_t\">20,37</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Airway, breathing, and circulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with significant CNS depression may lose protective airway reflexes and should be intubated, particularly in light of their lower seizure threshold. Short-acting neuromuscular blocking agents (eg, <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a>) are preferable, so as not to mask subsequent seizure activity. Induction agents with GABA agonist activity (eg, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>) may be preferable depending upon the patient's hemodynamic status.</p><p>Hypotension is initially treated with isotonic crystalloid. Caution should be exercised in patients at risk for volume overload, such as those with underlying heart disease or carbamazepine-induced myocardial dysfunction. Direct-acting vasopressors are used if intravenous fluids fail to correct the hypotension.</p><p class=\"headingAnchor\" id=\"H14450270\"><span class=\"h2\">QRS interval prolongation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sodium channel blockade may cause QRS interval prolongation and in other poisonings has been shown to predispose patients to ventricular arrhythmias [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/38,39\" class=\"abstract_t\">38,39</a>]. QRS prolongation due to <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity is treated with <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a>. A clear treatment threshold based upon the QRS duration has not been established; however, a reasonable practice is to give a bolus of 100 to 150 meq of sodium bicarbonate intravenously for QRS intervals longer than 110 milliseconds, particularly in patients with hypotension. Repeat boluses may be required. Treatment with sodium bicarbonate is described in detail separately. (See <a href=\"topic.htm?path=tricyclic-antidepressant-poisoning#H15\" class=\"medical medical_review\">&quot;Tricyclic antidepressant poisoning&quot;, section on 'Sodium bicarbonate for cardiac toxicity'</a>.)</p><p>We suggest avoiding class 1A (eg, <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a>) and 1C (eg, <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">flecainide</a>) antiarrhythmics in patients with acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning, although no studies have documented adverse effects from such treatment.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seizures caused by <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> overdose should be treated with gamma-aminobutyric acid (GABA) agonists, such as benzodiazepines (eg, <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a>). <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> administered as a continuous infusion for the sedation of intubated patients also functions as an effective anticonvulsant. There is <strong>no role</strong> for <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> in the management of carbamazepine-induced seizures [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/40\" class=\"abstract_t\">40</a>]. Electroencephalogram monitoring may be necessary in some patients.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Gastrointestinal decontamination</span></p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Activated charcoal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Activated charcoal (AC) remains the most common method of gastrointestinal (GI) decontamination for acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning, although its effectiveness in improving clinical outcomes has not been proven [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/41\" class=\"abstract_t\">41</a>]. The role of GI decontamination in the management of acute overdose is discussed separately. (See <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;</a>.)</p><p>It is acceptable to give a single dose of AC (1 <span class=\"nowrap\">g/kg;</span> maximum dose 50 g) to patients with a normal mental status who present within one to two hours of an acute overdose and are able to protect their airway [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/42,43\" class=\"abstract_t\">42,43</a>]. AC should be withheld in spontaneously breathing patients with CNS sedation who may not be able to protect their airway. We do <strong>NOT</strong> recommend that endotracheal intubation be performed solely for the purpose of giving charcoal.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Multidose activated charcoal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not empirically recommend multiple dose activated charcoal (MDAC) in the treatment of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity, as this implies scheduled administration of more than two doses of activated charcoal.&nbsp;Although&nbsp;some&nbsp;literature suggests&nbsp;a benefit&nbsp;in giving MDAC for severe carbamazepine toxicity [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/41,44-47\" class=\"abstract_t\">41,44-47</a>], there is little data to suggest&nbsp;improved outcomes and we do not believe that the benefits of this therapy outweigh the risks. (See <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient#H18993821\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;, section on 'Multidose activated charcoal'</a>.)</p><p>However, a second dose of activated charcoal&nbsp;may be given to patients who are not at risk for aspiration and in whom the therapy is not contraindicated by evidence of decreased intestinal motility noted on physical examination (eg, decreased bowel sounds) or imaging studies (eg, dilated bowel loops with air fluid levels). Care should always be taken to ascertain normal intestinal motility prior to administering activated charcoal. The anticholinergic effects of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> cause decreased bowel motility and predispose patients to the development of an ileus, which often precludes MDAC therapy.&nbsp;We suggest that any administration of activated charcoal beyond the initial dose be given in consultation with a medical toxicologist or poison control center. (See <a href=\"#H23\" class=\"local\">'Additional resources'</a> below.)</p><p>Although both the American Academy of Clinical Toxicologists and the European Association of Poisons Centres and Clinical Toxicologists recommend that treatment with MDAC be &quot;considered&quot; following <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> ingestions resulting in serious or life-threatening signs and symptoms, the authors note that there is no convincing evidence that MDAC reduces morbidity or mortality [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/44\" class=\"abstract_t\">44</a>]. </p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Other methods</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no role for other types of GI decontamination for acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning. Whole bowel irrigation after ingestion of sustained release tablets failed to reduce absorption in several reported cases [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8,48,49\" class=\"abstract_t\">8,48,49</a>], and we do <strong>not</strong> advocate its use. Gastric emptying (by syrup of ipecac or gastric lavage) is <strong>not</strong> recommended [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/50,51\" class=\"abstract_t\">50,51</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Extracorporeal elimination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest that extracorporeal removal of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> be reserved for severely poisoned patients who continue to deteriorate (as manifest by signs such as multiple refractory seizures, hemodynamic instability requiring vasopressors, or life-threatening dysrhythmias) despite maximum supportive care [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/52\" class=\"abstract_t\">52</a>]. Decisions regarding hemodialysis in the setting of carbamazepine intoxication should be made, whenever possible, in conjunction with a medical toxicologist. (See <a href=\"#H23\" class=\"local\">'Additional resources'</a> below.)</p><p>It remains questionable whether hemodialysis and related techniques enhance the elimination of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>. At therapeutic levels, carbamazepine is highly protein bound, limiting the effectiveness of extracorporeal elimination. </p><p>High-flux hemodialysis is the preferred approach to extracorporeal elimination in this setting. The clearance rate for hemodialysis is superior to continuous venovenous hemodialysis (CVVHD), but the technique may not be feasible in hemodynamically unstable patients and the effect on clinical outcome remains unknown [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/53,54\" class=\"abstract_t\">53,54</a>]. Data regarding clearance rates for CVVHD with or without albumin dialysate are underwhelming. Charcoal hemoperfusion can be effective but is often difficult to obtain [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8,55-59\" class=\"abstract_t\">8,55-59</a>], and the procedure entails risks (eg, thrombocytopenia, coagulopathy, hypothermia, hypocalcemia, hypophosphatemia, and hypoglycemia) [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/56-59\" class=\"abstract_t\">56-59</a>]. Plasmapheresis and plasma exchange have been used to enhance <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> elimination [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/60\" class=\"abstract_t\">60</a>], but outcome data are limited and use of these techniques cannot be recommended, pending further study. (See <a href=\"topic.htm?path=continuous-renal-replacement-therapy-in-acute-kidney-injury#H3419961088\" class=\"medical medical_review\">&quot;Continuous renal replacement therapy in acute kidney injury&quot;, section on 'Definition of CRRT modality'</a>.)</p><p>Despite substantial improvement in hemodialysis and continuous renal replacement therapy (CRRT) technology, evidence supporting extracorporeal elimination of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> in the setting of overdose remains limited to case reports and case series [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/53-55,61-65\" class=\"abstract_t\">53-55,61-65</a>]. Many of these reports use serum carbamazepine concentrations before and after hemodialysis or CRRT to gauge effectiveness, but this approach can be misleading. To judge carbamazepine clearance accurately, the concentration of carbamazepine in the dialysate should be measured. In addition, some authors hypothesize that the active metabolite carbamazepine-10,11 epoxide (CBZ&ndash;E), with its lower degree of protein binding, can be effectively cleared via extracorporeal modalities thereby limiting toxicity. However, quantitative levels of this metabolite are rarely measured.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Physostigmine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do <strong>not</strong> recommend the use of <a href=\"topic.htm?path=physostigmine-drug-information\" class=\"drug drug_general\">physostigmine</a> to treat patients suffering anticholinergic effects from acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> toxicity. Physostigmine's half-life is significantly shorter than carbamazepine's, and its therapeutic effects are transient compared to carbamazepine's toxicity. Moreover, carbamazepine's toxicity is not due solely to anticholinergic effects [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/66\" class=\"abstract_t\">66</a>]. The use of physostigmine for anticholinergic poisoning is found separately. (See <a href=\"topic.htm?path=anticholinergic-poisoning#H11\" class=\"medical medical_review\">&quot;Anticholinergic poisoning&quot;, section on 'Antidotal therapy with physostigmine'</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Other complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rhabdomyolysis requires aggressive hydration with intravenous fluids. Aspiration may warrant antibiotic therapy; mechanical ventilation may be necessary for respiratory failure. Hyponatremia may require urgent correction depending upon the rate and degree of the fall in the serum sodium concentration. (See <a href=\"topic.htm?path=aspiration-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Aspiration pneumonia in adults&quot;</a> and <a href=\"topic.htm?path=overview-of-the-treatment-of-hyponatremia-in-adults\" class=\"medical medical_review\">&quot;Overview of the treatment of hyponatremia in adults&quot;</a> and <a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury#H25398978\" class=\"medical medical_review\">&quot;Prevention and treatment of heme pigment-induced acute kidney injury&quot;, section on 'Prevention'</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">PEDIATRIC CONSIDERATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Of the <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> exposures reported in 2014, 470 involved children less than 19 years old. More than half of these were in patients under six years old [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Most pediatric ingestions produce only mild toxicity due to their accidental nature, and are characterized by ataxia, nystagmus, drowsiness, and emesis [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/19,27,67,68\" class=\"abstract_t\">19,27,67,68</a>]. Peripheral anticholinergic signs are frequently absent [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/27,67\" class=\"abstract_t\">27,67</a>]. The serum <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> concentration at which more severe manifestations of toxicity develop is estimated to be lower than that of adults [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/27,68\" class=\"abstract_t\">27,68</a>]. According to one case series, children with a serum carbamazepine concentration above 28 <span class=\"nowrap\">mcg/mL</span> (117 <span class=\"nowrap\">micromol/L)</span> are at highest risk of coma and apnea [<a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">ADDITIONAL RESOURCES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical presentations that are unclear (1-800-222-1222). The World Health Organization provides a listing of international poison centers at its website: <a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html&amp;token=vYXClxsD0hnrf4M8kYcoD1kMICrGjKQRRaFc8pA0pw9qlhpVmsmYh2e3Gi7webw9H9uSzH3nipQ0rPpTLYBWhGP+/wpQqUegRzvggwgKA6s=&amp;TOPIC_ID=332\" target=\"_blank\" class=\"external\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a></p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> toxicity frequently presents with neurologic and cardiovascular symptoms. Patients with mild carbamazepine toxicity, or those presenting shortly after ingestion, may demonstrate signs such as drowsiness, nystagmus, and tachycardia. Severe intoxication may manifest as lethargy, seizure, coma, hypotension, or arrhythmia. Signs and symptoms of anticholinergic toxicity are expected. Toxicity may be prolonged due to carbamazepine's delayed and erratic absorption. (See <a href=\"#H4\" class=\"local\">'Clinical features'</a> above and <a href=\"#H3\" class=\"local\">'Kinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Important historical information in the patient with suspected <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> poisoning includes:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Identity of any ingested pills, including dose and formulation (eg, immediate-release or controlled-release)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Time of ingestion</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Whether the patient takes <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> or any other medication chronically</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Possible coingestants (see <a href=\"#H5\" class=\"local\">'History'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> overdose, tachycardia is common. Hypotension may occur in more severe poisoning. Hyperthermia may result from anticholinergic effects or seizure activity. The patient may be agitated, but central nervous system (CNS) depression, ranging from drowsiness to coma, is more common. Fluctuations in consciousness are classically encountered in carbamazepine toxicity. Seizures can occur. (See <a href=\"#H6\" class=\"local\">'Examination and clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a> toxicity may present in a similar fashion to other poisonings (eg, anticholinergics, anticonvulsants, sedative hypnotics), as well as metabolic and other non-toxicologic disorders. Considerations include carbon monoxide poisoning, hypoglycemia, CNS infection, intracranial hemorrhage, and stroke. (See <a href=\"#H7\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> concentrations should be followed serially in an acute overdose. Concentrations may not peak for a few days; levels should be obtained every four to six hours until there is a definite downward trend and the patient is improving clinically. Other useful diagnostic tests (including electrocardiograms) are described in the text. (See <a href=\"#H8\" class=\"local\">'Laboratory evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with significant CNS depression may lose protective airway reflexes and should be intubated. Short-acting neuromuscular blocking agents are preferable, so as not to mask subsequent seizure activity. Induction agents with antiepileptic effects (eg, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>) may be preferable depending upon the patient's hemodynamic status. (See <a href=\"#H13\" class=\"local\">'Airway, breathing, and circulation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypotension is treated initially with intravenous boluses of isotonic crystalloid. Sodium channel blockade from <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> overdose may cause QRS prolongation and predispose to ventricular arrhythmias. We suggest that QRS prolongation caused by carbamazepine poisoning be treated with <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). One approach is to give boluses of 100 to 150 meq of sodium bicarbonate intravenously for QRS intervals longer than 100 milliseconds. Treatment with sodium bicarbonate is described in detail separately. (See <a href=\"topic.htm?path=tricyclic-antidepressant-poisoning#H15\" class=\"medical medical_review\">&quot;Tricyclic antidepressant poisoning&quot;, section on 'Sodium bicarbonate for cardiac toxicity'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest that seizures caused by <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> overdose be treated with GABA agonists such as benzodiazepines (eg, <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). There is <strong>no role</strong> for <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> or other anticonvulsants. (See <a href=\"#H14\" class=\"local\">'Seizures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is acceptable to give a single dose of AC (1 <span class=\"nowrap\">g/kg;</span> maximum dose 50 g) to patients with a normal mental status who present within one to two hours of an acute <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> overdose and are able to protect their airway. AC should be withheld in unintubated patients with CNS depression. We do <strong>NOT</strong> recommend that tracheal intubation be performed solely for the purpose of giving charcoal. We suggest that extracorporeal removal of carbamazepine be reserved for severely poisoned patients with signs of continued deterioration (eg, refractory seizures; hemodynamic instability requiring vasopressors; life-threatening dysrhythmias) despite maximum supportive care. (See <a href=\"#H15\" class=\"local\">'Gastrointestinal decontamination'</a> above and <a href=\"#H19\" class=\"local\">'Extracorporeal elimination'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/1\" class=\"nounderline abstract_t\">Mowry JB, Spyker DA, Brooks DE, et al. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila) 2015; 53:962.</a></li><li class=\"breakAll\">Novartis Pharmaceuticals USA. Prescribing information for Tegretol CR400(R) tablets www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (Accessed on August 27, 2008).</li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/3\" class=\"nounderline abstract_t\">Spiller HA. Management of carbamazepine overdose. Pediatr Emerg Care 2001; 17:452.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/4\" class=\"nounderline abstract_t\">Starmer CF, Lastra AA, Nesterenko VV, Grant AO. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation 1991; 84:1364.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/5\" class=\"nounderline abstract_t\">Fujiwara Y, Sato M, Otsuki S. Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology (Berl) 1986; 90:332.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/6\" class=\"nounderline abstract_t\">Van Calker D, Steber R, Klotz KN, Greil W. Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur J Pharmacol 1991; 206:285.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/7\" class=\"nounderline abstract_t\">Kanarkowski R, Rybakowski J. [Clinical pharmacokinetics of carbamazepine]. Psychiatr Pol 1989; 23:379.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/8\" class=\"nounderline abstract_t\">Graudins A, Peden G, Dowsett RP. Massive overdose with controlled-release carbamazepine resulting in delayed peak serum concentrations and life-threatening toxicity. Emerg Med (Fremantle) 2002; 14:89.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/9\" class=\"nounderline abstract_t\">Vree TB, Janssen TJ, Hekster YA, et al. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Ther Drug Monit 1986; 8:297.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/10\" class=\"nounderline abstract_t\">Spina E, Martines C, Fazio A, et al. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther Drug Monit 1991; 13:109.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/11\" class=\"nounderline abstract_t\">Kanarkowski R, Wankiewicz G, Lehmann W, Rybakowski J. Pharmacokinetics of carbamazepine in psychiatric patients. Pol J Pharmacol Pharm 1988; 40:55.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/12\" class=\"nounderline abstract_t\">Yoo JH, Kang DS, Chun WH, et al. Anticonvulsant hypersensitivity syndrome with an epoxide hydrolase defect. Br J Dermatol 1999; 140:181.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/13\" class=\"nounderline abstract_t\">Hundt HK, Aucamp AK, M&uuml;ller FO. Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage. Hum Toxicol 1983; 2:607.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/14\" class=\"nounderline abstract_t\">Goulden KJ, Camfield P, Dooley JM, et al. Severe carbamazepine intoxication after coadministration of erythromycin. J Pediatr 1986; 109:135.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/15\" class=\"nounderline abstract_t\">Tagawa T, Mimaki T, Ono J, et al. Erythromycin-induced carbamazepine intoxication in two epileptic children. Jpn J Psychiatry Neurol 1989; 43:513.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/16\" class=\"nounderline abstract_t\">Jerling M, Lindstr&ouml;m L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16:368.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/17\" class=\"nounderline abstract_t\">Iwahashi K, Miyatake R, Suwaki H, et al. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 1995; 18:233.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/18\" class=\"nounderline abstract_t\">Winnicka RI, Topaci&#324;ski B, Szymczak WM, Szyma&#324;ska B. Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide. J Toxicol Clin Toxicol 2002; 40:759.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/19\" class=\"nounderline abstract_t\">Perez A, Wiley JF. Pediatric carbamazepine suspension overdose-clinical manifestations and toxicokinetics. Pediatr Emerg Care 2005; 21:252.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/20\" class=\"nounderline abstract_t\">Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp 1989; 4:95.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/21\" class=\"nounderline abstract_t\">Spiller HA, Carlisle RD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002; 40:81.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/22\" class=\"nounderline abstract_t\">Tibballs J. Acute toxic reaction to carbamazepine: clinical effects and serum concentrations. J Pediatr 1992; 121:295.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/23\" class=\"nounderline abstract_t\">O'Neal W Jr, Whitten KM, Baumann RJ, et al. Lack of serious toxicity following carbamazepine overdosage. Clin Pharm 1984; 3:545.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/24\" class=\"nounderline abstract_t\">Fisher RS, Cysyk B. A fatal overdose of carbamazepine: case report and review of literature. J Toxicol Clin Toxicol 1988; 26:477.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/25\" class=\"nounderline abstract_t\">Hojer J, Malmlund HO, Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine alone. J Toxicol Clin Toxicol 1993; 31:449.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/26\" class=\"nounderline abstract_t\">Seymour JF. Carbamazepine overdose. Features of 33 cases. Drug Saf 1993; 8:81.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/27\" class=\"nounderline abstract_t\">Stremski ES, Brady WB, Prasad K, Hennes HA. Pediatric carbamazepine intoxication. Ann Emerg Med 1995; 25:624.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/28\" class=\"nounderline abstract_t\">de la Cruz M, Bance M. Carbamazepine-induced sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 1999; 125:225.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/29\" class=\"nounderline abstract_t\">Tsao CY, Wright FS. Acute chemical pancreatitis associated with carbamazepine intoxication. Epilepsia 1993; 34:174.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/30\" class=\"nounderline abstract_t\">Godden DJ, McPhie JL. Bullous skin eruption associated with carbamazepine overdosage. Postgrad Med J 1983; 59:336.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/31\" class=\"nounderline abstract_t\">Brahmi N, Kouraichi N, Abderrazek H, et al. Clinical experience with carbamazepine overdose: relationship between serum concentration and neurological severity. J Clin Psychopharmacol 2008; 28:241.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/32\" class=\"nounderline abstract_t\">George S, Braithwaite RA. A preliminary evaluation of five rapid detection kits for on site drugs of abuse screening. Addiction 1995; 90:227.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/33\" class=\"nounderline abstract_t\">Fleischman A, Chiang VW. Carbamazepine overdose recognized by a tricyclic antidepressant assay. Pediatrics 2001; 107:176.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/34\" class=\"nounderline abstract_t\">Saidinejad M, Law T, Ewald MB. Interference by carbamazepine and oxcarbazepine with serum- and urine-screening assays for tricyclic antidepressants. Pediatrics 2007; 120:e504.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/35\" class=\"nounderline abstract_t\">Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990; 24:1214.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/36\" class=\"nounderline abstract_t\">Kuz GM, Manssourian A. Carbamazepine-induced hyponatremia: assessment of risk factors. Ann Pharmacother 2005; 39:1943.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/37\" class=\"nounderline abstract_t\">Mayoral W, Lewis JH. Drug-induced liver disease. Curr Opin Gastroenterol 2000; 16:231.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/38\" class=\"nounderline abstract_t\">Bradberry SM, Thanacoody HK, Watt BE, et al. Management of the cardiovascular complications of tricyclic antidepressant poisoning : role of sodium bicarbonate. Toxicol Rev 2005; 24:195.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/39\" class=\"nounderline abstract_t\">Liebelt EL. Targeted management strategies for cardiovascular toxicity from tricyclic antidepressant overdose: the pivotal role for alkalinization and sodium loading. Pediatr Emerg Care 1998; 14:293.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/40\" class=\"nounderline abstract_t\">Cave G, Sleigh JW. ECG features of sodium channel blockade in rodent phenytoin toxicity and effect of hypertonic saline. Vet Hum Toxicol 2003; 45:254.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/41\" class=\"nounderline abstract_t\">Mise S, Juki&#263; I, Tonki&#263; A, et al. Multidose activated charcoal in the treatment of carbamazepine overdose with seizures: a case report. Arh Hig Rada Toksikol 2005; 56:333.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/42\" class=\"nounderline abstract_t\">Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/43\" class=\"nounderline abstract_t\">Greene S, Harris C, Singer J. Gastrointestinal decontamination of the poisoned patient. Pediatr Emerg Care 2008; 24:176.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/44\" class=\"nounderline abstract_t\">Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999; 37:731.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/45\" class=\"nounderline abstract_t\">Wason S, Baker RC, Carolan P, et al. Carbamazepine overdose--the effects of multiple dose activated charcoal. J Toxicol Clin Toxicol 1992; 30:39.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/46\" class=\"nounderline abstract_t\">Brahmi N, Kouraichi N, Thabet H, Amamou M. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. Am J Emerg Med 2006; 24:440.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/47\" class=\"nounderline abstract_t\">Montoya-Cabrera MA, Sauceda-Garc&iacute;a JM, Escalante-Galindo P, et al. Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. Arch Med Res 1996; 27:485.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/48\" class=\"nounderline abstract_t\">Thanacoody R, Caravati EM, Troutman B, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila) 2015; 53:5.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/49\" class=\"nounderline abstract_t\">Lurie Y, Bentur Y, Levy Y, et al. Limited efficacy of gastrointestinal decontamination in severe slow-release carbamazepine overdose. Ann Pharmacother 2007; 41:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/50\" class=\"nounderline abstract_t\">Vale JA, Kulig K, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42:933.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/51\" class=\"nounderline abstract_t\">Position paper: Ipecac syrup. J Toxicol Clin Toxicol 2004; 42:133.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/52\" class=\"nounderline abstract_t\">Ghannoum M, Yates C, Galvao TF, et al. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2014; 52:993.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/53\" class=\"nounderline abstract_t\">Harder JL, Heung M, Vilay AM, et al. Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. Hemodial Int 2011; 15:412.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/54\" class=\"nounderline abstract_t\">Choi JS, Kim CS, Bae EH, et al. Enhanced clearance of carbamazepine using albumin-containing dialysate during CVVHDF. Intensive Care Med 2013; 39:159.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/55\" class=\"nounderline abstract_t\">Bek K, Ko&ccedil;ak S, Ozkaya O, et al. Carbamazepine poisoning managed with haemodialysis and haemoperfusion in three adolescents. Nephrology (Carlton) 2007; 12:33.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/56\" class=\"nounderline abstract_t\">Deshpande G, Meert KL, Valentini RP. Repeat charcoal hemoperfusion treatments in life threatening carbamazepine overdose. Pediatr Nephrol 1999; 13:775.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/57\" class=\"nounderline abstract_t\">Leslie PJ, Heyworth R, Prescott LF. Cardiac complications of carbamazepine intoxication: treatment by haemoperfusion. Br Med J (Clin Res Ed) 1983; 286:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/58\" class=\"nounderline abstract_t\">Cameron RJ, Hungerford P, Dawson AH. Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. J Toxicol Clin Toxicol 2002; 40:507.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/59\" class=\"nounderline abstract_t\">Pilapil M, Petersen J. Efficacy of hemodialysis and charcoal hemoperfusion in carbamazepine overdose. Clin Toxicol (Phila) 2008; 46:342.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/60\" class=\"nounderline abstract_t\">Duzova A, Baskin E, Usta Y, Ozen S. Carbamazepine poisoning: treatment with plasma exchange. Hum Exp Toxicol 2001; 20:175.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/61\" class=\"nounderline abstract_t\">Ram Prabahar M, Raja Karthik K, Singh M, et al. Successful treatment of carbamazepine poisoning with hemodialysis: a case report and review of the literature. Hemodial Int 2011; 15:407.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/62\" class=\"nounderline abstract_t\">Chetty M, Sarkar P, Aggarwal A, Sakhuja V. Carbamazepine poisoning: treatment with haemodialysis. Nephrol Dial Transplant 2003; 18:220.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/63\" class=\"nounderline abstract_t\">Schuerer DJ, Brophy PD, Maxvold NJ, et al. High-efficiency dialysis for carbamazepine overdose. J Toxicol Clin Toxicol 2000; 38:321.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/64\" class=\"nounderline abstract_t\">Li TG, Yan Y, Wang NN, Zhao M. Acute carbamazepine poisoning treated with resin hemoperfusion successfully. Am J Emerg Med 2011; 29:518.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/65\" class=\"nounderline abstract_t\">Garlich FM, Goldfarb DS. Have advances in extracorporeal removal techniques changed the indications for their use in poisonings? Adv Chronic Kidney Dis 2011; 18:172.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/66\" class=\"nounderline abstract_t\">Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/67\" class=\"nounderline abstract_t\">Macnab AJ, Birch P, Macready J. Carbamazepine poisoning in children. Pediatr Emerg Care 1993; 9:195.</a></li><li><a href=\"https://www.uptodate.com/contents/carbamazepine-poisoning/abstract/68\" class=\"nounderline abstract_t\">Lifshitz M, Gavrilov V, Sofer S. Signs and symptoms of carbamazepine overdose in young children. Pediatr Emerg Care 2000; 16:26.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 332 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PHARMACOLOGY AND CELLULAR TOXICOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">KINETICS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL FEATURES</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">History</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Examination and clinical manifestations</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">LABORATORY EVALUATION</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">General diagnostic testing in overdose</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Serum carbamazepine concentration</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Ancillary testing</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">MANAGEMENT</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Airway, breathing, and circulation</a></li><li><a href=\"#H14450270\" id=\"outline-link-H14450270\">QRS interval prolongation</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Seizures</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Gastrointestinal decontamination</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Activated charcoal</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Multidose activated charcoal</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Other methods</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">Extracorporeal elimination</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Physostigmine</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Other complications</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">PEDIATRIC CONSIDERATIONS</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">ADDITIONAL RESOURCES</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"EM/332|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/76992\" class=\"graphic graphic_table\">- Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anticholinergic-poisoning\" class=\"medical medical_review\">Anticholinergic poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aplastic-anemia-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aspiration-pneumonia-in-adults\" class=\"medical medical_review\">Aspiration pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=benzodiazepine-poisoning-and-withdrawal\" class=\"medical medical_review\">Benzodiazepine poisoning and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=carbon-monoxide-poisoning\" class=\"medical medical_review\">Carbon monoxide poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-acute-bacterial-meningitis-in-adults\" class=\"medical medical_review\">Clinical features and diagnosis of acute bacterial meningitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-heme-pigment-induced-acute-kidney-injury\" class=\"medical medical_review\">Clinical features and diagnosis of heme pigment-induced acute kidney injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rhabdomyolysis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of rhabdomyolysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=continuous-renal-replacement-therapy-in-acute-kidney-injury\" class=\"medical medical_review\">Continuous renal replacement therapy in acute kidney injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis\" class=\"medical medical_review\">Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-allergy-classification-and-clinical-features\" class=\"medical medical_review\">Drug allergy: Classification and clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient\" class=\"medical medical_review\">Gastrointestinal decontamination of the poisoned patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatic-encephalopathy-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Hepatic encephalopathy in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypoglycemia-in-adults-clinical-manifestations-definition-and-causes\" class=\"medical medical_review\">Hypoglycemia in adults: Clinical manifestations, definition, and causes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke\" class=\"medical medical_review\">Initial assessment and management of acute stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-epilepsy-in-adults\" class=\"medical medical_review\">Overview of the management of epilepsy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-hyponatremia-in-adults\" class=\"medical medical_review\">Overview of the treatment of hyponatremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=phenytoin-poisoning\" class=\"medical medical_review\">Phenytoin poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury\" class=\"medical medical_review\">Prevention and treatment of heme pigment-induced acute kidney injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seizures-and-epilepsy-in-children-initial-treatment-and-monitoring\" class=\"medical medical_review\">Seizures and epilepsy in children: Initial treatment and monitoring</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tricyclic-antidepressant-poisoning\" class=\"medical medical_review\">Tricyclic antidepressant poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=valproic-acid-poisoning\" class=\"medical medical_review\">Valproic acid poisoning</a></li></ul></div></div>","javascript":null}